Pamela Munster

Alessa Therapeutics is a clinical-stage biopharmaceutical company focused on developing localized drug delivery systems for the treatment of solid tumors, particularly prostate and breast cancers. Founded in 2018 by Dr. Pamela Munster, a prominent oncologist at the University of California, San Francisco (UCSF), the company utilizes a proprietary non-biodegradable polymer implant technology to deliver high concentrations of therapeutic agents directly to the tumor site. This localized approach is designed to maximize efficacy while minimizing the systemic toxicity and side effects often associated with oral or intravenous cancer therapies. The company's lead candidate, Enolen, is an intraprostatic implant eluting the anti-androgen enzalutamide, which is currently in Phase 1 clinical trials and received FDA Fast Track designation in early 2026.